These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23210957)

  • 1. Prevalence of Linea nigra in patients with benign prostatic hyperplasia and prostate carcinoma.
    Okeke LI; George AO; Ogunbiyi AO; Wachtel M
    Int J Dermatol; 2012 Nov; 51 Suppl 1():41-3, 45-8. PubMed ID: 23210957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
    Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the epidemiology and natural history of benign prostatic hyperplasia.
    Boyle P
    Prog Clin Biol Res; 1994; 386():3-18. PubMed ID: 7528398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies.
    Bouraoui Y; Ben Jemaa A; Rodriguez G; Ben Rais N; Fraile B; Paniagua R; Sellemi S; Royuela M; Oueslati R
    Pathol Biol (Paris); 2012 Oct; 60(5):301-5. PubMed ID: 21889270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study.
    Stamatiou K; Alevizos A; Agapitos E; Sofras F
    Prostate; 2006 Sep; 66(12):1319-28. PubMed ID: 16688747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
    Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
    Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
    Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
    Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid hormone receptors and endocrine response of prostatic carcinoma.
    Jasper WS; Abou-Issa H; Gogate SA; Snider GB
    Cancer Detect Prev; 1987; 10(5-6):393-9. PubMed ID: 2436783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
    Binnie MC; Alexander FE; Heald C; Habib FK
    Prostate; 2005 Jun; 63(4):309-15. PubMed ID: 15599941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden.
    Chokkalingam AP; Nyrén O; Johansson JE; Gridley G; McLaughlin JK; Adami HO; Hsing AW
    Cancer; 2003 Oct; 98(8):1727-34. PubMed ID: 14534890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and tissue selenium concentrations and glutathione peroxidase activities in patients with prostate cancer and benign prostate hyperplasia.
    Zachara BA; Szewczyk-Golec K; Tyloch J; Wolski Z; Szylberg T; Stepien S; Kwiatkowski S; Bloch-Boguslawska E; Wasowicz W
    Neoplasma; 2005; 52(3):248-54. PubMed ID: 15875088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
    Ricote M; García-Tuñón I; Bethencourt FR; Fraile B; Paniagua R; Royuela M
    Cancer; 2004 Apr; 100(7):1388-96. PubMed ID: 15042672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF; Shibaeva AN; Ianshin AA; Urenkov SB; Mironova OS; Kazantseva IA; Kushlinskiĭ NE
    Urologiia; 2004; (1):17-21. PubMed ID: 15022438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.